Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis
Igor Kolos, Alexandr Troitskiy, Tatiana Balakhonova, Merab Shariya, Denis Skrypnik, Tatiana Tvorogova, Alexandr Deev, Sergey Boytsov, Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) Study Group, Lana R Akezheva, Nikolay V Dupik, Alexandra I Ershova, Igor S Fedotenkov, Vera I Fyodorova, Robert I Khabazov, Mikhail M Loukianov, Mariya Nikonova, Nataliya A Shevchenko, Ekaterina Yu Stepanyants, Elizaveta Yu Strazden, Mariya I Tripoten, Nataliya V Ust'yantseva, Igor Kolos, Alexandr Troitskiy, Tatiana Balakhonova, Merab Shariya, Denis Skrypnik, Tatiana Tvorogova, Alexandr Deev, Sergey Boytsov, Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) Study Group, Lana R Akezheva, Nikolay V Dupik, Alexandra I Ershova, Igor S Fedotenkov, Vera I Fyodorova, Robert I Khabazov, Mikhail M Loukianov, Mariya Nikonova, Nataliya A Shevchenko, Ekaterina Yu Stepanyants, Elizaveta Yu Strazden, Mariya I Tripoten, Nataliya V Ust'yantseva
Abstract
Objective: This study assessed the value of modern medical treatment (MMT) with and without carotid endarterectomy (CEA) in patients with asymptomatic severe carotid artery stenosis.
Methods: We conducted a randomized trial involving 55 patients with 70% to 79% carotid stenosis at three Russian centers. Between 2009 and 2013, 31 patients were randomized to undergo CEA with MMT (CEA group) and 24 to receive MMT alone. The primary end point was nonfatal ipsilateral stroke or death from any cause during a follow-up period of 5.0 years. The secondary end point was any nonfatal stroke, carotid revascularization, or death from any cause during follow-up.
Results: The trial was stopped after a median follow-up of 3.3 years (maximum, 5.0 years). There were two primary events in the CEA group and nine events in the MMT group. The 3.3-year cumulative primary event rates were 6.5% in the CEA group and 37.5% in the MMT group (hazard ratio for the MMT group, 5.06; 95% confidence interval, 1.53-16.79; P = .008). The 3.3-year cumulative secondary end point was 12.9% in the CEA group and 50.0% in the MMT group (hazard ratio for the MMT group, 4.23; 95% confidence interval, 1.55-11.53; P = .0048).
Conclusions: CEA as an initial management strategy could reduce the risk of death and major cerebrovascular events when added to MMT.
Trial registration: ClinicalTrials.gov NCT00805311.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
Source: PubMed